In a murine model, it has been shown that systemically delivered siRNAs targeting the EglN prolyl hydroxylases suppress hepcidin levels specifically in the liver, leading to improved RBC production in models of anemia [102]. This evidence concerns the gene HAMP and anemia (phenotype).